| abstract |
A method for inhibiting a cysteine protease which consists in providing patients with an effective amount of a compound selected from the group consisting of: 2- [N- (N-benzyloxycarbonylglycinyl)] - 2 '- [N' - (N-benzyloxy -carbonyl-L-leucinyl)] carbohydrazide; (3RS) -1- (N-benzyloxycarbonyl-L-leucinyl) -3- [N- (4-phenoxy-benzoyl) amino] pyrrolidin-4-one; (1S) - N- [2- [1- (N-Benzyloxycarbonylamino) -3-methylbutyl] -thiazol-4-ylcarbonyl] -N '- [N- (2-pyridinylmethoxycarbonyl) -L-leucinyl] hydrazide; 1- (N-benzyloxycarbonyl-L-leuccinylamino) -3- (2-benzyloxy-phenylsulfonyl) amino-propan-2-one; N- [2- (2-benzyloxyphenyl) thiazol-4-ylcarbonyl] -N '- [ N- (3-pyridinylmethoxycarbonyl) -L-leuccinyl] hydrazide; (1S) -N- [1- (N-benzyloxycarbonylamino) -3-methylbutyl] -thiazol-4-ylcarbonyl] -N´- [N- (3- pyridinylmethoxycarbonyl) -L-leucinyl] hydrazide; 1- [N- (4-morpholinocarbamoyl) -L-leuccinylamino] -3- (4-phenoxyphenylsulfonyl) amino-propan-2-one; N- [2- (1-naphthyl) thiazol-4-ylcarbonyl] -N ' - [N- (4-pyridinylmethoxycarbonyl) -L-leucinyl] hydrazide; N- [2- (2-benzyloxyphenyl) thiazol-4-ylcarbonyl] -N '- (N-pyrazinecarbonyl-L-leucinyl) hydrazide; N- [ N- (1-Benzyl-5-methylimidazol-4-ylcarbonyl) -L-leucinyl] -N '- [2- (1-naphthyl) thiazol-4-ylcarbonyl] hydrazide; (3RS) -3- [N- ( 3-benzyloxybenzoyl) -L-leuccinylamino] etrahydrofuran-4-one; N- [2- (cyclopropyl-N- (2-methylpropyl) amino] thiazol-4-yl-carbonyl] -N '- (5-methyl-2 -phenyloxazol-4-ylcarbonyl) -L-leucinyl] hydrazide; 1- [3- (2-pyridinyl) phenylacetylamino] -3- [N- (2-thiophenecarbonyl) -L-leucinylamino] propan -2-one; (3S ) -3- [N (benzothiazol-6-ylcarbonyl) -L-leucinylamino] -1- [3- (2-pyridinyl) phenylacetylamino] butan-2-one; N- [2- [N-cyclopropyl-N- ( 2-methylpropyl) amino] thiazol-4-yl-carbonyl] -N '- [N- (7-methoxybenzofuran-2-ylcarbonyl) -L-β-cyclopropylalanyl] hydrazide; 1- [N- (benzoxazol-5-ylcarbonyl) ) -L-Leucinylamino] -3- [3- (2-pyridinyl) phenylacetylamino] propan-2-one; 1- [ N- [4- [2- (N, N-dimethylamino) ethoxy] benzoyl] -L-leucinylamino] -3- [3- (2-pyridinyl) phenylacetylamino] propan-2-one; and N- [2- [N-cyclopropyl-N- (2-methylpropyl) amino] thiazol-4-yl-carbonyl] - -N '- [N- [5- [2- (N, N-dimethylamino) ethoxy] benzofuran-2-ylcarbonyl-L-β-cyclopropylalanyl] hydrazide, a method according to point one in which the administration of said compounds is made on patients affected by infection of parasites such as: Plasmodium falciparum, Trypanosoma cruzi, Trypanosoma brucei , Mexican Leishmania, Leishmania pifanoi, Leishmania major, Schistosoma mansoni, Onchocerca volvulus, brujia pahangi, Entamoeba histolytica, Giardia lamblia, Helminths Haemonchus contortus and Fasciola hepatic, helminths of the genera Spirometra, tricinella, Necator and Asca of Necator genera Cryptosporidium, Eimeria, Toxoplasma and Naegleria. |